Protocol Ledger

NCT05261139 · Phase III · RECRUITING

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Interventional Phase III clinical trial protocol NCT05261139 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-07 Enrollment: 160 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05261139
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05261139
Protocol FieldVerified Registry Value
NCT IdentifierNCT05261139
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment160 participants (ESTIMATED)
Registered Start Date2022-03-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI